Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1968 2
1971 1
1972 1
1980 1
1982 1
1983 1
1987 1
1995 1
1997 2
1998 1
2003 1
2004 1
2006 2
2007 3
2008 1
2010 2
2011 2
2012 4
2013 2
2014 2
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Emery JG, et al. Among authors: dul e. J Biol Chem. 1998 Jun 5;273(23):14363-7. doi: 10.1074/jbc.273.23.14363. J Biol Chem. 1998. PMID: 9603945 Free article.
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
Goodman KB, Cui H, Dowdell SE, Gaitanopoulos DE, Ivy RL, Sehon CA, Stavenger RA, Wang GZ, Viet AQ, Xu W, Ye G, Semus SF, Evans C, Fries HE, Jolivette LJ, Kirkpatrick RB, Dul E, Khandekar SS, Yi T, Jung DK, Wright LL, Smith GK, Behm DJ, Bentley R, Doe CP, Hu E, Lee D. Goodman KB, et al. Among authors: dul e. J Med Chem. 2007 Jan 11;50(1):6-9. doi: 10.1021/jm0609014. J Med Chem. 2007. PMID: 17201405
Development of a high-throughput screen to detect inhibitors of TRPS1 sumoylation.
Brandt M, Szewczuk LM, Zhang H, Hong X, McCormick PM, Lewis TS, Graham TI, Hung ST, Harper-Jones AD, Kerrigan JJ, Wang DY, Dul E, Hou W, Ho TF, Meek TD, Cheung MH, Johanson KO, Jones CS, Schwartz B, Kumar S, Oliff AI, Kirkpatrick RB. Brandt M, et al. Among authors: dul e. Assay Drug Dev Technol. 2013 Jun;11(5):308-25. doi: 10.1089/adt.2012.501. Assay Drug Dev Technol. 2013. PMID: 23772552
A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
Ott HM, Graves AP, Pappalardi MB, Huddleston M, Halsey WS, Hughes AM, Groy A, Dul E, Jiang Y, Bai Y, Annan R, Verma SK, Knight SD, Kruger RG, Dhanak D, Schwartz B, Tummino PJ, Creasy CL, McCabe MT. Ott HM, et al. Among authors: dul e. Mol Cancer Ther. 2014 Dec;13(12):3062-73. doi: 10.1158/1535-7163.MCT-13-0876. Epub 2014 Sep 24. Mol Cancer Ther. 2014. PMID: 25253781
Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.
Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL, Smith GK, Chen Z, Webb C, Khandekar S, Yi T, Kirkpatrick R, Dul E, Jolivette L, Marino JP Jr, Willette R, Lee D, Hu E. Doe C, et al. Among authors: dul e. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. doi: 10.1124/jpet.106.110635. Epub 2006 Oct 3. J Pharmacol Exp Ther. 2007. PMID: 17018693
Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
Sehon CA, Wang GZ, Viet AQ, Goodman KB, Dowdell SE, Elkins PA, Semus SF, Evans C, Jolivette LJ, Kirkpatrick RB, Dul E, Khandekar SS, Yi T, Wright LL, Smith GK, Behm DJ, Bentley R, Doe CP, Hu E, Lee D. Sehon CA, et al. Among authors: dul e. J Med Chem. 2008 Nov 13;51(21):6631-4. doi: 10.1021/jm8005096. Epub 2008 Oct 9. J Med Chem. 2008. PMID: 18842034
31 results